CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net (loss) income from operations	$ (16,930,289)	$ (2,100,850)
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	5,153,695	2,733,455
Non-cash loss on the sale of Infusionz and select assets, net	2,212,542	0
Gain on forgiveness of PPP loan	0	300,995
Gain on sale of assets	0	(5,500)
Inventory write-offs	118,990	1,044,607
Bad debt expense	0	131,968
Amortization of consideration discount	969,098	0
Amortization of senior security original issue discount	62,408	0
Impairment of goodwill and intangible assets	3,746,301	0
Non-controlling interest	(559,967)	54,820
Change in deferred tax asset	(3,139,227)	(1,061,238)
Shares issued for services	0	576,774
Shares issued for finder fee	1,770	0
Stock based compensation	3,664,538	2,755,016
Changes in assets and liabilities, net of acquired amounts
Accounts receivable	476,256	284,998
Inventory	1,260,479	(2,795,486)
Prepaid expenses and other assets	168,499	284,653
Operating lease payable	132,555	37,922
Accounts payable and accrued liabilities	3,180,049	(446,609)
Deferred revenue	0	(478,385)
Net cash provided by operating activities - Continuing Operations	517,697	715,150
Net cash used in operating activities - Discontinued Operations	(315,021)	(895,981)
Net cash provided by operating activities	202,676	(180,831)
Cash flows from investing activities
Acquisition of Lucky Tail	(3,528,239)	0
Acquisition of VitaMedica, Inc., net of cash acquired	(500,000)	(2,574,589)
Acquisition of New England Technology, Inc.	(2,051,587)	0
Acquisition of Cygnet	(1,050,000)	(1,028,763)
Acquisition of Interactive Offers, net of cash acquired	0	(1,854,193)
Proceeds from the sale of Infusionz and selected assets	5,492,532
Acquisition of property and equipment	(937,564)	(5,451,773)
Proceeds from the sale of equipment	6,000
Net cash used in investing activities - Continuing Operations	(2,574,858)	(10,903,318)
Net cash (used in) provided by investing activities - Discontinued Operations	0	0
Net cash used in investing activities	(2,574,858)	(10,903,318)
Cash flows from financing activities
Repayment of notes payable	(445,670)	(1,002,874)
Repayment of SBA note payable	(305,482)	0
Repayment of the senior convertible notes payable	(6,305,406)	0
Proceeds of the senior convertible notes payable	0	6,678,506
Payment on line of credit, net	(6,318,234)	0
Proceeds on note payable on building	3,000,000	0
Proceeds from the issuance of stock, net	6,127,893
Stock repurchase program	$ 0	$ (1,975,888)
Repayment on note payable on building	(158,434)	0
Proceeds from issuance of convertible debt	$ 2,650,000
Proceeds on note payable, related party	1,470,000	$ 0
Net cash used in financing activities - Continuing Operations	(285,333)	3,699,744
Net cash (used in) provided by financing activities - Discontinued Operations	0	0
Net cash used in financing activities	(285,333)	3,699,744
Net decrease in cash - Continuing Operations	(2,342,494)	(6,488,424)
Net decrease in cash - Discontinued Operations	(315,021)	(895,981)
Cash, beginning of year	7,149,806	14,534,211
Cash, end of year	4,492,291	7,149,806
Supplemental cash flow disclosures
Interest paid	2,278,292	64,460
Income tax paid	0	656,000
Non-cash financing activities
Issuance of common stock for acquisition of Infusionz	0	1,764,876
Issuance of common stock for acquisition of VitaMedica	0	482,000
Issuance of debt for acquisition of VitaMedica	0	1,000,000
Liabilities assumed from acquisition of VitaMedica	$ 0	$ (309,574)
Issuance of common stock for interest expenses	607,004	0
Issuance of commons stock for services	$ 140,700	$ 140,700
Issuance of common stock for acquisition of E-Core	6,000,000	0
Liabilities assumed from acquisition of E-Core	(7,712,168)	0
Operating assets designated as held for sale	1,026,043	10,790,984
Liabilities assumed from acquisition of VitaMedica	0	(309,574)
Issuance of stock for acquisition of Interactive	0	2,733,628
Liabilities assumed from acquisition of Cygnet	$ 0	$ 9,472,438